Pitfalls and Pathways in Prescription Drug Promotion:
|
|
- Cornelia Warren
- 7 years ago
- Views:
Transcription
1 Pitfalls and Pathways in Prescription Drug Promotion: Or what every healthcare auditor should know before she watches another drug ad! Paul Savidge Vice President Global Labeling & Promotion Compliance Bristol-Myers Squibb October 18, 2007
2 Let s be spontaneous Regulation of Drug Advertising My Welsh Terrier Thinks He s Mark Spitz Topic Select-o-Matic Why the Designated Hitter has Ruined Baseball 10 Reasons Philadelphia is Better Than New York I was Jane Austen in a Former Life
3 My Welsh Terrier Thinks He s Mark Spitz Paul Savidge Interesting and Spontaneous Person October 18, 2007
4 Disclaimer My opinions are my own and do not necessarily represent the views or practices of my employer. You are free to disagree with me. Most of my friends do.
5 What I will discuss today Fundamentals of FDA regulation of prescription drug promotion Hot enforcement trends and issues Auditing the promotion compliance function Recent amendments to the FFDCA* *Federal Food, Drug & Cosmetic Act of 1938
6 FDA s Powers FDA has broad authority to ensure that drugs are sufficiently safe and effective prior to their introduction into the marketplace. Since 1962, the FFDCA has given FDA responsibility to regulate the advertising of: Prescription human drugs Prescription veterinary drugs Biologics Restricted medical devices
7 Why? Why did Congress give FDA oversight of prescription drug advertising? Congress concluded that advertising can mislead health care professionals to the detriment of patient health. To encourage companies to submit clinical data to FDA to support new indications.
8 CDER has responsibility for drugs FDA s Center of Drug Evaluation and Research (CDER) has oversight for human prescription drugs and therapeutic biologics HUMAN CDER s Office of Medical Policy includes the Division of Drug Marketing, Advertising, and Communications (DDMAC) DDMAC oversees advertising and promotional activities for prescription drugs and therapeutic biologics
9 DDMAC DDMAC is headed by a Division Director, (Tom Abrams) with staff divided into Four Professional Review Groups Two Direct-to-Consumer (DTC) Review Groups A Training & Support Group DDMAC s mission is to protect the public health by ensuring that prescription drug/therapeutic biologic information is Truthful Balanced Accurately communicated
10 What does DDMAC do? DDMAC fulfills its mission through a variety of activities: Provides advice to the pharmaceutical industry, usually through Advisory Comments Performs surveillance of promotional activities Through sponsors submissions of promotional materials Through attendance at major scientific conferences Through complaints from industry, healthcare professionals, consumers Initiates enforcement actions Issues guidance documents for industry Conducts research on promotion topics, such as consumer behavior towards DTC advertising
11 An important limitation FDA has limited authority to require the review of advertising prior to its use* Sponsors may request DDMAC to provide advisory comments on promotional materials prior to their use DDMAC will not provide advisory comments on promotional claims that are already in the marketplace All promotional materials must be submitted to DDMAC before or at the time of initial use on Form *Recently expanded by Congress!
12 Relevant regulations Labeling Part 201 Prescription Drug Advertising Part 202 Prescription Drug Marketing Part 203 Investigational New Drug (IND) Application Part 312 New Drug Applications (NDA) Part 314 Post-Marketing Submission of Advertising Part Accelerated Approval Part Sub Part H Accelerated Approval for Biologics Part Dissemination of Information on Unapproved/New Uses Part 99 Dear Healthcare Professional Letters Part Information to Pharmacists Part 200.7
13 Drug labeling The regulations define labeling: Labeling is all labels and other written, printed, or graphic matter Upon product container or wrapper Accompanying such product Label is a subset of labeling and is defined as a display of written, printed, or graphic matter upon the immediate container of any article Each product approved in the United States has Prescribing Information (PI) that is the FDA approved product labeling Labeling also includes promotional labeling, which is distinct from advertising
14 Promotional labeling v. advertisements Regulations do not define advertising. Examples provided by FDA suggest that advertisements are forms of promotion that occupy a paid space such as broadcast, magazine and newspaper ads Promotional labeling is essentially all other types of promotion such as sales aids, patient pamphlets, company-owned internet sites and verbal communications Why should I care about the difference?
15 Why the difference is important Print advertisements that make product claims must be accompanied by a brief summary A brief summary is a document that contains detailed information about a drug s safety profile based on information contained in approved product labeling. Promotional labeling that makes product claims must be accompanied by the approved Prescribing Information (the PI)
16 Advertising regulations 21 CFR Part 202 provides the requirements related to: The placement of the brand and generic name of the product Reminder advertisements Indication statement Presentation of information Must not be false or misleading Must have fair balance between efficacy and risk information Must be consistent with and not contrary to approved labeling Must not omit material facts
17 False, lacking in fair balance or otherwise misleading 21 CFR Part 202 provides a list of ways in advertisements (or promotional labeling) are or may be false, lacking in fair balance or otherwise misleading Fair balance is the requirement that information concerning the efficacy of a product must be adequately balanced by information concerning the product s safety Safety information should be communicated in a way that is reasonably comparable in prominence and readability to the communication of information regarding a product s efficacy Note: Although fair balance is a concept, the term is often used to refer to the safety information that is required to be communicated
18 What is false or misleading?? Promotional material is false or misleading if facts not in the labeling are stated or implied to support claims that the drug is: Better or more effective than indicated Useful for a broader range of patients than in the approved labeling Safer, or has fewer serious side effects or contraindications than indicated by then labeling
19 What is false or misleading? Examples of ways in which promotional material may be false or misleading: Presents a misleading comparison that suggests the product is safer or more effective than another drug, or otherwise unfairly compares two products Misrepresents a study or study results Uses graphics in a misleading way Misrepresents the drug s mechanism of action or its clinical impact Uses price information in a misleading fashion
20 Promotional claims must be adequately substantiated Most promotional and labeling claims must be supported by substantial evidence Substantial evidence typically is two or more adequate and well-controlled clinical investigations Limited instances where FDA has required fewer than two studies for safety and efficacy claims By statute, certain claims to managed care formulary committee members must be supported by competent and reliable scientific evidence
21 Promoting an unapproved drug as safe or effective is prohibited. A sponsor, investigator, or any person acting for or on behalf of a sponsor or investigator cannot represent that an investigational drug is safe or effective. Opportunities to publicize investigational compounds are very limited: Legitimate clinical recruitment activities Press releases concerning significant scientific events Required SEC disclosures (material events) Coming Soon advertisements under certain circumstances
22 Accelerated approval Accelerated approval is a process to speed to market drugs that promise significant benefit over existing therapy for serious or life-threatening illnesses or for which no therapy exists Because drugs approved under the accelerated approval provisions are approved based on incomplete information (and therefore their risk/benefit is less clear), FDA requires that all promotional materials for these drugs be submitted to DDMAC for comments prior to use.
23 The role of guidance documents FDA often communicates its current thinking on certain topics to the pharmaceutical industry through guidance documents FDA views these guidance documents as recommendations, unless specific regulatory or statutory requirements are cited Guidance documents do not create or confer any rights for or on any person and do not operate to bind FDA or the public (although this has been debated in the courts)
24 Guidance documents concerning drug promotion Final Guidance Documents Industry-Supported Scientific and Educational Activities Consumer-Directed Broadcast Advertisements Draft Guidance Documents Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements Help-Seeking and Other Disease Awareness Communications by or on Behalf of Drug or Device Firms Accelerated Approval Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling
25 The flood gates are opened: Final guidance on Consumer-Directed Broadcast Advertisements (1999) Purpose: Provide guidance on advertising prescription drugs directly to consumers through broadcast media such as television, radio, or telephone Summary Adequate Provision for dissemination of the approved labeling must be made for prescription drug advertisements that are made through a broadcast media and cannot contain a brief summary Broadcast advertisements must disclose the product s major risks in either the audio or audio and visual parts of the presentation, commonly known as a Major Statement
26 What is adequate provision? To comply with the adequate provision requirement, the guidance recommends that broadcast ads include reference to the following sources of additional information: A toll-free telephone number A concurrently running DTC print ad A healthcare professional An Internet web page providing access to product information
27 Hot Enforcement Trends and Issues
28 DDMAC enforcement actions Most common enforcement actions (EAs) are: UNTITLED LETTER Typically addressed to the company s regulatory reviewer and signed by the DDMAC reviewer Requires immediate discontinuation of the violative materials and confirmation in writing within 2 weeks WARNING LETTER Titled and typically addressed to the CEO of the company and signed by the Division Director Requires immediate discontinuation of the violative materials and confirmation in writing within 2 weeks Includes request for corrective action Note: Warning letters usually concern serious safety issues or address a pattern of abuse by the sponsor
29 DDMAC Enforcement Trends: Decreased Volume of EAs over the Past Decade Total EAs Total Warning Letters Number of EAs * 7* * Year *through 9/30/07
30 DDMAC Enforcement Trends: Increased Proportion of Warning Letters 100 Proportion of WL/EA, % Proportion of WL/EA, % * * Year *through 9/30/07
31 Trends in 2007 DDMAC Enforcement* Therapeutic Areas Ophthalmology 7% Rheumatology 7% Oncology 7% Neurology 26% Psychiatry 7% Allergy 13% Dermatology 13% Antiinfectives 20% *through 9/30/07
32 Trends in 2007 DDMAC Enforcement* Material types 40% advertisements 40% sales aids Target audience Professional 87% (6 of 13 WL) Consumer 13% (1 of 2 WL) *through 9/30/07
33 Top Issues in 2007 DDMAC Enforcement* Unsubstantiated claims 67% of EAs cite lack of substantial evidence Unsubstantiated efficacy or safety claims Overstatement of efficacy Unsubstantiated comparative claims Omission and/or minimization of risk information 60% of EAs cite lack of adequate presentation of safety information Promotion of off-label or unapproved uses 33% of EAs cite implied or overt off-label promotion *through 9/30/07.
34 Companies are responsible for their agents! Provigil (modafinil) [C-IV] WL Promotional material was presented by a physician consultant hired by Cephalon, Inc. to present to the Maryland Department of Health and Mental Hygiene s Pharmacy and Therapeutics Committee
35 If its not good enough for the PI, it s probably not good enough for promotion Exelon (rivastigmine tartrate) Capsules and Oral Solution WL
36 When the auditors came knocking
37 Audit methodology Objectives Evaluate department s compliance with FDA requirements and internal standards and procedures Assess the effectiveness of the review process Assess management and training Methods Review of standard operating procedures Review of sample of approved promotional materials against regulations, policies and standards Interviews of personnel
38 Pathways Audit was able to assess: Quality of review/approval/archival system Level of commitment to compliance Scope and depth of regulatory training Effectiveness of process (not just SOPs but level of implementation and enforcement) Quality of process training for all personnel involved Level of commitment to continuous improvement
39 Pitfalls Limited scope of this audit, which did not include: Interviews with or evaluation of other stakeholders and participants in the process In-depth review of promotional materials (inclusive of product history, previous communications with DDMAC, etc ) Review of other promotional and nonpromotional activities of the company (compliance activities, grant policies, public relations, advisory boards, market research)
40 Recent Amendments to the FFDCA related to drug promotion
41 FDAAA & PDUFA On September 27, 2007, President Bush signed into law the Food and Drug Administration Amendments Act (FDAAA) of 2007, which includes the reauthorization and expansion of the Prescription Drug User Fee Act (PDUFA) (effective in 180 days) The amendments and reauthorization of PDUFA will significantly broaden and upgrade the agency's drug safety program, increase resources for review of television drug advertising, and facilitate more efficient development of safe and effective new medications for the American public
42 Highlights FDA can require pre-review of DTC advertisements under certain circumstances Direction on major safety statement in broadcast advertisements Toll free adverse experience reporting number in published advertisements Civil money penalties for DTC advertising violations Separate user fee program for review of DTC television ads
43 Pre-review of television ads The FDAAA grants FDA broad authority to require the submission of any television advertisement for a drug, 45 days prior to broadcast FDA may make recommendations on: Changes necessary to protect the consumer good and well-being Changes consistent with prescribing information for the product Statements to address the efficacy of the drug in specific population groups (e.g., elderly, children and racial and ethnic groups) FDA may require the sponsor to include a specific disclosure about a serious risk listed in the product labeling or the date of approval of the drug
44 Major statement in broadcast ads DTC broadcast ads (other than reminder ads) must present the major statement relating to side effects and contraindications in a clear, conspicuous, and neutral manner This requirement is designed to address concerns that background distractions undercut the communication of safety information in DTC broadcast ads FDA must issue regulations within 30 months of amendment s enactment establishing standards for determining whether a major statement meets this new standard
45 Toll-free AE reporting number in advertisements The amendment requires published DTC ads to include information, including a number, about how consumers can report side effects to FDA Within 6 months of amendment s enactment, FDA must conduct a study to determine whether this information is appropriate for inclusion in DTC television ads "You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call FDA-1088."
46 New penalties for DTC ad violations FDA has new authority to impose money penalties against the NDA/BLA holder that disseminates any DTC ad (including print) that is false or misleading First violation $250,000 for any 3-year period Subsequent violation $500,000 in any 3-year period Repeated dissemination of the same or similar ad constitutes a single violation After written notice by FDA, however, each day constitutes a separate violation except that for print ads in publications that are published less frequently than daily, each issue date (e.g., weekly, monthly) is considered a single violation
47 User fees for DTC broadcast advertisements Separate user fee program for sponsors that submit DTC television ads for advisory review will pay fees Fees to be collected annually, adjusted for inflation and workload, will fund 27 DDMAC FTE for pre-market advisory review of TV advertisements Stable funding design: one-time participation fee in first year, and annual pre-payment for advisory reviews Five year phased-in performance FDA will commit to review specified number of ads submitted for advisory reviews in 45 days, and specified number of resubmissions in 30 days
48 Mechanism for collection 120 days before start of FY08 (or start of program if statute delayed), FDA will issue a Federal Register (FR) notice asking persons to identify number of TV ads they intend to submit for advisory review during FY08 Response will be a commitment to pay the advisory review fees for the identified submissions The ad shall be submitted in the FY for which the fee was assessed, except that A person can carry-over one paid fee to the next FY
49 Mechanism for collection Based on the number of submissions identified, 60 days before start of FY08 or program, FDA will issue another FR establishing the fees for FY08 Fees will be $6.25 million divided by the number of submissions identified e.g., if 150 submissions are identified, fee will be $6.25 million 150 = $42,000 Fee per submission may not exceed $83,000 in first year
50 Mechanism for collection FDA will invoice companies for fees Fees due and payable on or before October 1 of FY 50% Late fees For late payment of invoices For advisory reviews not identified before start of fiscal year
51 Mechanism of collection: participation fee One time only assessment, either before start of program in FY08, or when company decides to seek advisory reviews Designed to collect $6.25 million (one year of reserves) FDA will assess each participating sponsor for an amount equal to that assessed for the annual advisory review fees in the first year of program Payment is graduated based on number of advisory reviews
52 Late fees and end of program Late participants will be assessed at least as much as those who joined in FY08 Participation fee will capture all ads submitted for advisory review during first year of participation, even if identified late (and will be 50% more if late fees applied to advisory reviews) In FY12, or if program ends early, any money remaining, less expenses needed to close down the program, will be returned to sponsors
53 Next time we ll talk about baseball! Thank you very much
Introduction to Compliance with FDA Labeling and Advertising Requirements
Introduction to Compliance with FDA Labeling and Advertising Requirements Second Annual Pharmaceutical Industry Regulatory and Compliance Summit Dick Kenny FDA History Basic function of government Oldest
More informationGuidance for Industry Consumer-Directed Broadcast Advertisements
Guidance for Industry Consumer-Directed Broadcast Advertisements U.S. Department of Health and Human Services Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research
More informationGuidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationGuidance for Industry
Guidance for Industry Consumer-Directed Broadcast Advertisements Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationInterplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation
Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Leslie M. Tector Quarles & Brady LLP September 30, 2014 Objectives Which federal
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Guidance for Industry DRAFT GUIDANCE This guidance document
More informationAmgen GLOBAL CORPORATE COMPLIANCE POLICY
1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers and temporary staff worldwide ( Covered Persons ). Consultants, contract workers,
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Sources of Regulation 502(n) added to the FD&C Act in the Kefauver-Harris
More informationWALKING THE COMPLIANCE LINE: A REGULATORY LAWYER S PERSPECTIVE
WALKING THE COMPLIANCE LINE: A REGULATORY LAWYER S PERSPECTIVE Presented By: Alan B. Minsk Partner and Chair, Food and Drug Practice Team Arnall Golden Gregory LLP alan.minsk@agg.com Presented To: ISMPP
More informationFDA Fast Track and Priority Review Programs
Order Code RS22814 February 21, 2008 FDA Fast Track and Priority Review Programs Summary Susan Thaul Specialist in Drug Safety and Effectiveness Domestic Social Policy Division By statutory requirements
More informationRegulatory Affairs Professionals Society: Regulatory Affairs Certification (RAC) Study Group FDA Regulation of Advertising and Promotion
Regulatory Affairs Professionals Society: Regulatory Affairs Certification (RAC) Study Group FDA Regulation of Advertising and Promotion Alex Toy July 14, 2013 1 Agenda FDA Regulatory Framework Office
More informationRegulation of Prescription Drug Promotion
Regulation of Prescription Drug Promotion Amy Toscano, Pharm.D., RAC, CPA Team Leader Office of Prescription Drug Promotion Food and Drug Administration June 2013 Overview Office of Prescription Drug Promotion
More informationGAO PRESCRIPTION DRUGS. Improvements Needed in FDA s Oversight of Direct-to-Consumer Advertising. Report to Congressional Requesters
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 PRESCRIPTION DRUGS Improvements Needed in FDA s Oversight of Direct-to-Consumer Advertising GAO-07-54
More informationFair Balance on the Internet: A Review of Recent DDMAC Enforcement Action. By Alyson Sous, PharmD
Fair Balance on the Internet: A Review of Recent DDMAC Enforcement Action By Alyson Sous, PharmD 28 The Internet presents drug manufacturers and distributors with a significant opportunity to communicate
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationGuidance for Industry
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed
More informationApplication Submitted on Received on Supplement type NDA 021875/S-005 July 24, 2008 July 25, 2008 Changes Being Effected
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021875/S-005, S-008, S-015 SUPPLEMENT APPROVAL Cephalon Inc. Attention: Paul Kirsch Senior Director and Group
More informationRE: NDA: 021876 DICLEGIS (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets, for oral use MA # 350 WARNING LETTER
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Eric Gervais, Executive Vice President 919 Conestoga Road Building
More informationHow To Weigh Data From A Study
PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties
More informationGuidance for Industry
Guidance for Industry Promoting Medical Products in a Changing Healthcare Environment; I. Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies (PBMs) DRAFT GUIDANCE
More informationGuidance for Industry
Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of
More informationHealthcare Law Compliance Guide (commonly known as the White Guide)
Pfizer Inc 235 East 42nd Street New York, NY 10017 www.pfizer.com Dear Colleagues: At Pfizer, we are committed to upholding the highest standards when we interact with physicians, healthcare organizations,
More informationGoals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
More informationWARNING LETTER. Angus Russell Chief Executive Officer Shire Development Inc. 725 Chesterbrook Blvd. Wayne, PA 19087-5637
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Angus Russell Chief Executive Officer Shire Development Inc. 725 Chesterbrook
More informationGuidance for Industry
Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationGuidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationFDA S MONITORING OF POSTMARKETING STUDY COMMITMENTS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA S MONITORING OF POSTMARKETING STUDY COMMITMENTS Daniel R. Levinson Inspector General June 2006 OEI-01-04-00390 Office of Inspector
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics DRAFT GUIDANCE This guidance
More informationGuidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More information247 CMR: BOARD OF REGISTRATION IN PHARMACY
247 CMR 9.00: CODE OF PROFESSIONAL CONDUCT; PROFESSIONAL STANDARDS FOR REGISTERED PHARMACISTS, PHARMACIES AND PHARMACY DEPART- MENTS Section 9.01: Code of Professional Conduct for Registered Pharmacists,
More informationDUVAL CLIENT ALERT December 2009
1 P a g e DUVAL CLIENT ALERT December 2009 In this DUVAL CLIENT ALERT, we list practical ways medical device companies can lawfully communicate about their products prior to FDA clearance or approval.
More informationMarketing, e-commerce and advertising in the pharmaceutical industry: France, the UK and the US
Life Sciences 2007/08 Marketing, e-commerce and advertising in the pharmaceutical industry: France, the UK and the US Alison Dennis, Paule Drouault-Gardrat and Areta Kupchyk, Reed Smith www.practicallaw.com/0-379-0848
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Peter A. Lankau President and CEO 100 Endo Boulevard Chadds Ford, PA
More informationPOLICY STATEMENT. Guidelines for Refractive Surgery Advertising
POLICY STATEMENT Guidelines for Refractive Surgery Advertising A joint statement of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery and the International
More informationGuidance for Industry Classifying Resubmissions in Response to Action Letters
Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationMedical Billing and Agency Formal Disputes
Guidance for Industry Formal Dispute Resolution: Appeals Above the Division Level Additional copies of this Guidance are available from: Office of Training and Communications Division of Communications
More informationGuidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
More informationStrategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA
Strategies to Prepare for Meetings with the FDA Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Topics for Discussion Who Are We? How Do We Interact Internally? Why
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Internet/Social Media Platforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
More informationWARNING LETTER. Ian C. Reed Chairman and Chief Executive Officer Pfizer Inc. 235 East 42 nd Street New York, NY 10017
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 Ian C. Reed Chairman and Chief Executive Officer 235 East 42 nd Street New York, NY 10017
More informationGuidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.
Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human
More informationPOLICY AND PROCEDURES OFFICE OF NEW DRUGS. NDAs and BLAs: Communication to Applicants of Planned Review Timelines.
CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 6010.8 Rev. 1 POLICY AND PROCEDURES OFFICE OF NEW DRUGS NDAs and BLAs: Communication to Applicants of Planned Review Timelines Table of Contents PURPOSE...1
More informationList of Guiding Principles Promoting Good Governance in the Pharmaceutical Sector 1
List of Guiding Principles Promoting Good Governance in the Pharmaceutical Sector 1 1. Good governance in the pharmaceutical sector 1.1 The List of Guiding Principles is based on recognition by all participants
More informationPOLICY STATEMENT. Guidelines for Refractive Surgery Advertising. Statement of Purpose:
POLICY STATEMENT Guidelines for Refractive Surgery Advertising Statement of Purpose: These guidelines are designed to assist ophthalmologists in providing truthful, informative advertising of refractive
More informationFlorida Administrative Code
Florida Administrative Code Rule 69B-220.051 Conduct of Public Adjusters. (1) Purpose and Scope. This rule sets forth department policy as to certain matters generally affecting public adjusters. Procedures
More informationU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance
Guidance for Industry Prescription Drug Marketing Act Donation of Prescription Drug Samples to Free Clinics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationPromoting Medical Products Globally
Promoting Medical Products Globally Handbook of Pharma and MedTech Compliance United States of America This publication is copyright. Apart from any fair dealing for the purpose of private study or research
More informationWhy do we have Speaker Compliance Guidelines and Training?
Disclaimer The views expressed in this presentation are the views of the facilitators and do not necessarily represent the views or policies of our employer. Why do we have Speaker Compliance Guidelines
More informationWARNING LETTER. According to its approved product labeling (PI) (in pertinent part, emphasis original):
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993-0002 TRANSMITTED BY FACSIMILE Sapan A. Shah, Ph.D. President and Chief Executive Officer
More informationWARNING LETTER. Multikine is an investigational new drug that does not have marketing authorization in the United States. (b) (4)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Geert R. Kersten Director and Chief Executive Officer 8229 Boone
More informationPrescription Drug Information for Patients: History
Prescription Drug Information for Patients: History 1500s: Ethical Statutes of Royal College of Physicians Let no physician teach the people about medicines or even tell them the names of the medicines,
More informationIACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013
Exempt Sections within the Food, Drug, and Cosmetic Act If a "traditional compounder", defined as a licensed pharmacist or licensed physician, meets ALL conditions within Section 503A, the compounder is
More informationADVERTISING/SALES PROMOTION REQUIREMENTS (Updated June 25, 2009)
ADVERTISING/SALES PROMOTION REQUIREMENTS (Updated June 25, 2009) This document provides a general overview of the advertising/sales promotion requirements under the state franchise registration laws. As
More informationPublic Law 110 85 110th Congress An Act
PUBLIC LAW 110 85 SEPT. 27, 2007 121 STAT. 823 Public Law 110 85 110th Congress An Act To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs
More informationPRIVACY NOTICE. In certain situations, we may also disclose patient information to another provider or health plan for their health care operations.
1 PRIVACY NOTICE THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY. This Privacy Notice is being
More informationGuidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products
Guidance for Industry Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products Small Entity Compliance Guide Written comments and suggestions may be
More informationNauru Utilities Corporation Act 2011
REPUBLIC OF NAURU Nauru Utilities Corporation Act 2011 Act No. 13 of 2011 Table of Provisions PART 1 PRELIMINARY MATTERS... 1 1 Short title... 1 2 Commencement... 1 3 Purposes... 1 4 Definitions... 2 PART
More informationReport to Congress. Implementation of Section 3507 of the Patient Protection and Affordable Care Act of 2010. Second Progress Report
Report to Congress Implementation of Section 3507 of the Patient Protection and Affordable Care Act of 2010 Second Progress Report Food and Drug Administration May 2012 Margaret Hamburg, M.D. Commissioner
More informationPOLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR. Table of Contents
POLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR Tracking of Significant Safety issues in Marketed Drugs -- Use of the DARRTS Tracked Safety Issues Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...2
More informationE-ALERT Food & Drug 2012 END-OF-YEAR SUMMARY OF FDA PROMOTIONAL ENFORCEMENT ACTIVITY OFFICE OF PRESCRIPTION DRUG PROMOTION (OPDP) ENFORCEMENT ACTIVITY
E-ALERT Food & Drug March 18, 2013 2012 END-OF-YEAR SUMMARY OF FDA PROMOTIONAL ENFORCEMENT ACTIVITY This client alert reviews the warning and untitled letters issued in 2012 by the Office of Prescription
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationMinimum Performance and Service Criteria for Medicare Part D
Minimum Performance and Service Criteria for Medicare Part D 1. Terms and Conditions. In addition to the other terms and conditions of the Pharmacy Participation Agreement ( Agreement ), the following
More informationGuidance for Industry
Guidance for Industry Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act U.S. Department of Health and Human Services Office of Financial Management June 1999 User Fees Guidance for
More informationREGULATION. on the advertising of medicinal products. SECTION I Definitions, scope and general provisions.
REGULATION on the advertising of medicinal products. SECTION I Definitions, scope and general provisions. Article 1 Definitions. For the purposes of this Regulation, the following terms are used as defined
More information(1) Purpose and Scope. This rule sets forth department policy as. to certain matters generally affecting public adjusters and public
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Florida Administrative Code 69B-220.051 Conduct of Public Adjusters. (1) Purpose and Scope. This rule sets forth department policy as to certain matters
More informationGuidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationYoungevity Essential Life Sciences & Youngevity International, Inc.
Youngevity Essential Life Sciences & Youngevity International, Inc. Guidelines for Distributor created and maintained websites The following excerpts from Youngevity s Policies and Procedures are compiled
More informationMEMORANDUM. The Officers and Directors of the Company. Publicity Before and After Filing an IPO Registration Statement
MEMORANDUM TO: FROM: The Officers and Directors of the Company Fenwick & West LLP DATE: December 15, 2011 RE: Publicity Before and After Filing an IPO Registration Statement United States federal securities
More informationSeries 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING
West Virginia Title 210 LEGISLATIVE RULE GOVERNOR S OFFICE OF HEALTH ENHANCEMENT AND LIFESTYLE PLANNING (GOHELP) Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING 210-1-1. General. 1.1. Scope. --
More informationGuidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide U.S. Department of Health and Human Services Center for Drug Evaluation and
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationLIBRARY GUIDE: Pharmaceutical Sales & Marketing
LIBRARY GUIDE: Pharmaceutical Sales & Marketing Page 2 Pharmaceutical Sales and Marketing Course Library Table of Contents: Courses Listed by Functional Area... 4 Basics of the PhRMA Code (PHSM01)...5
More informationNDA 021879 NDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021879 NDA APPROVAL Avanir Pharmaceuticals Attention: Randall Kaye, M.D. Vice President, Clinical and Medical
More informationUnofficial Consolidation
CENTRAL BANK (SUPERVISION AND ENFORCEMENT) ACT 2013 (SECTION 48) (LENDING TO SMALL AND MEDIUM-SIZED ENTERPRISES) REGULATIONS 2015 (S.I. No. 585 of 2015) Unofficial Consolidation This document is an unofficial
More informationHealthcare Law Compliance Guide (commonly known as the White Guide)
Pfizer Inc 235 East 42nd Street New York, NY 10017 www.pfizer.com Dear Colleagues: At Pfizer, we are committed to upholding the highest standards when we interact with physicians, healthcare organizations,
More informationGuidance for Industry
Guidance for Industry Submitting Debarment Certification Statements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationInformation Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office
More informationGuidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols
Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols For questions on the content of this document contact Leonard Wilson, CBER at 301-827-0373 or Susan Johnson, CDER
More informationGuidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration
More informationAn Examination of Consumer Perceptions of Direct to Consumer Prescription Drug Advertisements
An Examination of Consumer Perceptions of Direct to Consumer Prescription Drug Advertisements And Implications for Current Food and Drug Administration Oversight of Direct to Consumer Advertisement Regulations
More informationFDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY Daniel R. Levinson Inspector
More informationRe: Guidance for Industry Fees for Human Drug Compounding Outsourcing Facilities Under The Federal Food, Drug and Cosmetic Act
May 30, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room. 1061 Rockville, Maryland 20852 [Docket No. FDA-2014-D-0329]
More informationNDA 202439/S-008 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 202439/S-008 SUPPLEMENT APPROVAL Janssen Pharmaceuticals, Inc. ATTENTION: Alla Rhoge Pharm.D., Associate
More informationNOTICE OF THE NATHAN ADELSON HOSPICE PRIVACY PRACTICES
THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION PLEASE REVIEW IT CAREFULLY. DEFINITIONS PROTECTED HEALTH INFORMATION (PHI):
More information(4) In communications made through interactive media, such as the Internet, online services, and software, the required disclosures shall:
16 CODE OF FEDERAL REGULATIONS PART 322 MORTGAGE ASSISTANCE RELIEF SERVICES RULE (All provisions of the rule except the advance-fee ban will become effective December 29, 2010. The advance-fee ban provisions
More informationU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
More informationPOLICY AND PROCEDURES OFFICE OF PHARMACEUTICAL SCIENCE
POLICY AND PROCEDURES OFFICE OF PHARMACEUTICAL SCIENCE CLARIFICATION TELECONFERENCES BETWEEN SPONSORS, APPLICANTS, OR MASTER FILE HOLDERS AND THE ONDQA REVIEW TEAM Table of Contents PURPOSE...1 BACKGROUND...2
More information9129 Monroe Rd. Suite 100, Charlotte, NC 28270
9129 Monroe Rd. Suite 100, Charlotte, NC 28270 THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE READ IT CAREFULLY.
More informationUse of Electronic Health Record Data in Clinical Investigations
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationUpdate on Medicare Part D: 2009 and Beyond
Update on Medicare Part D: 2009 and Beyond 2009 NACDS Pharmacy & Technology Conference Christine C. Rinn Donald L. Bell, II Outline of Presentation» Introduction/Background on Part D» Trends in Part D»
More informationElectronic Information Systems
WASHINGTON REPORT Electronic Information Systems New Systems Promote Drug Development and Patient Safety Jill Wechsler FDA expands electronic data submission programs to improve regulatory operations and
More informationAPMI CODE OF PRACTICE ON ADVERTISING OF MEDICINAL PRODUCTS ISSUE 1
APMI CODE OF PRACTICE ON ADVERTISING OF MEDICINAL PRODUCTS ISSUE 1 August 2010 1. Introduction... 2 2. Scope... 3 3. Definitions... 4 4. General rules of advertising of medicinal products... 6 5. Advertising
More informationFDA Presentation - Society for Clinical Research Sites
FDA Presentation - Society for Clinical Research Sites FDA Presentation - Dr. Richard Moscicki, MD FDA CDER Deputy Director for Clinical Research Sites Faculty Disclosure In compliance with ACCME Guidelines,
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More information2013 Medicare. Part D Fraud, Training. First Tier, Downstream and Related Entities
2013 Medicare Advantage and Part D Fraud, Waste and Abuse Waste, Training First Tier, Downstream and Related Entities February, 2013 Training Objectives 1 Why is Fraud, Waste, and Abuse (FWA) Training
More informationPrinciples Governing Advertising in Publications of the American Medical Association
Principles Governing Advertising in Publications of the American Medical Association Revised December 2012 These principles, developed jointly by editorial and publishing staff, are applied by the American
More informationOFFICE OF INSPECTOR GENERAL
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA s Review Process for New Drug Applications A Management Review JANET REHNQUIST INSPECTOR GENERAL MARCH 2003 OEI-01-01-00590 OFFICE
More informationINTERNATIONAL STANDARD ON AUDITING 250 CONSIDERATION OF LAWS AND REGULATIONS IN AN AUDIT OF FINANCIAL STATEMENTS CONTENTS
INTERNATIONAL STANDARD ON AUDITING 250 CONSIDERATION OF LAWS AND REGULATIONS (Effective for audits of financial statements for periods beginning on or after December 15, 2009) CONTENTS Paragraph Introduction
More informationGuidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects
Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More information